Belarus to Test GenoMed's Novel Approach to West Nile Virus Encephalitis
Monday April 26, 8:45 am ET
ST. LOUIS, April 26 /PRNewswire-FirstCall/ -- GenoMed, Inc. (Pink Sheets: GMED - News), a Next Generation Disease Management(TM) company that uses its expertise in genomics to improve patient outcomes, said today that the leading experts in West Nile virus encephalitis in Belarus will collaborate with the Company in treating cases of suspected West Nile virus encephalitis this summer. Belarus, formerly a part of the USSR, is now an independent, democratic country of 10.5 million people which lies between Poland and Russia; its capital is Minsk.
ADVERTISEMENT
Researchers from the Research Institute for Epidemiology & Microbiology (RIEM) in Minsk, Belarus, consisting of Dr. Tamara Samoilova, Head of the Lab of Arboviral Infections, Professor of Immunology Leonid Titov, Director of the RIEM, and Professor of Neurology Joseph Protas, Head of the Lab of Viral Neuroinfections will test GenoMed's protocol for viral encephalitis in Belarus this summer. Normally, there are 50,000 patients with fever every year in Belarus, including 300 cases of viral encephalitis of uncertain cause. Dr. Samoilova has shown that West Nile virus accounts for a significant fraction of the patients with fever and previously undiagnosed viral encephalitis.
The protocol developed by GenoMed uses drugs currently in use by primary care physicians in every country, available in every drug store, and already proven to be safe. The Belarusian experts share GenoMed's belief that encephalitis and death result from an over-response by a person's immune system to the West Nile virus. GenoMed's protocol, which is patent-pending, gently suppresses the immune system, thus potentially saving the patient from paralysis or death.
GenoMed's treatment has a 100% cure rate so far among immunocompetent patients, including the elderly. No human vaccine yet exists for West Nile virus, nor is any other treatment as inexpensive, safe, or already available like GenoMed's.
GenoMed is conducting a free clinical trial for West Nile virus this summer in the United States as well as Belarus, and hopes also to recruit patients from Canada, Israel, Europe, and the Middle East. Patients can enroll by clicking on the "West Nile Trial" button at genomedics.com .
Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, is a Harvard- and Oxford-educated physician, who trained for seven years in Internal Medicine, Biochemistry, and Nephrology at Washington University School of Medicine in St. Louis before spending 11 years on the faculty of St. Louis University School of Medicine. He is a noted pioneer in the field of medical genomics, and has been recognized for his groundbreaking treatment of diseases associated with the angiotensin I-converting enzyme, such as chronic renal failure due to hypertension or type II diabetes. Dr. Moskowitz's novel approach to viral disease, including West Nile virus encephalitis, avian influenza (bird flu), and SARS, are regarded as innovative and potentially useful treatments for currently incurable diseases.
About GenoMed
GenoMed is leading the worldwide medical revolution which medical genomics has already made possible. GenoMed is a Next Generation Disease Management(TM) company whose mission is to improve patient outcomes by identifying the genetic pathways that cause disease. The Company is currently marketing its treatment to prevent kidney failure due to diabetes and high blood pressure, and to delay emphysema.
Safe Harbor Statement
This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether our treatment for West Nile virus encephalitis continues to be as effective as it has been so far; (b) whether sufficient medication is available and affordable in Belarus; (c) whether our server holds up to international demand; (d) our research and development being subject to other economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
biz.yahoo.com |
